



Aarey

DRUGS & PHARMACEUTICALS LTD.

**MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com
REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ☎ : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

14th October,2016

To,
Dept. of Corporate Services
The Bombay Stock Exchange Ltd
1st floor, Rotunda Building,
M.S.Marg, Mumbai-400 001.

Sub : Outcome of Board Meeting held on 14th October,2016

Scrip Code : 524412

Dear Sir,

This is to inform you that the Board of Directors of the company at its meeting held today, i.e. 14th October,2016, have passed the following resolutions :

The Board of Directors of the company has considered the Un-audited financial results for the quarter year ended 30th September,2016

Kindly take record of the above.

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd


Authorised Signatory

Encl.: a/a



**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS &
DEALERS OF CHEMICALS & SOLVENTS**

CIN No.: L99999MH1990PLC056538

H. O. : 107,204, SAHAKAR BHAVAN, 340 / 48, N. N. STREET, MASJID BUNDER, MUMBAI - 400 009. ☎ : (022) 66312998 / 66154219 Fax : 66154219 E-mail : info@aareydrugs.com
REGD. OFF. & FACTORY : E - 34, M.I.D.C., TARAPUR, BOISAR, DIST - THANE - 401506 ☎ : (02525) 271049 E-mail : corporate@aareydrugs.com Web : www.aareydrugs.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER'2016							₹ In Lacs
Sr No.	PARTICULARS	3 MONTHS ENDED			6 MONTHS ENDED		YEAR ENDED
		30.09.2016	30.06.2016	30.09.2015	30.09.2016 Consolidated	30.09.2015	31.03.2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Income from Sales/Services	8240.46	9461.18	3221.36	17701.64	7406.31	24602.87
2	Cost of Sales/Services	7937.77	9202.31	3160.67	17140.08	7218.26	24267.08
	a. Increase/Decrease in stock in trade & work in progress	----	----	----	----	----	----
	b. Consumption of Raw Materials	----	----	----	----	----	----
	c. Purchase of traded goods	----	----	----	----	----	----
	d. Other Expenditure	----	----	----	----	----	----
3	Gross Profit (1-2)	302.69	258.87	60.69	561.56	188.05	335.79
4	General Administrative Expenses	87.01	49.43	44.10	136.44	114.15	192.16
5	Selling and Distribution Expenses	5.17	20.25	10.06	25.42	23.94	55.42
6	Depreciation	36.10	34.73	21.87	70.83	43.75	61.89
7	Operating Profit before Interest (3) - (4+5+6)	174.41	154.46	-15.34	328.87	6.21	26.32
8	Interest	85.19	120.90	40.15	206.09	75.46	158.71
9	Exceptional Items	0	0	0	0	0	0
10	Operating Profit after Interest and Exceptional Items (7-8-9)	89.22	33.56	-55.49	122.78	-69.25	-132.39
11	Other Income	79.14	76.55	100.70	155.69	174.55	313.69
12	Profit (+)/Loss (-) from Ordinary Activities before tax (10+11)	168.36	110.11	45.21	278.47	105.30	181.30
13	Tax Expenses	0.00	0.00	0.00	0.00	0.00	52.36
14	Net Profit (+)/Loss (-) from ordinary Activities after tax (12-13)	168.36	110.11	45.21	278.47	105.30	128.94
15	Extraordinary items (net of tax expenses)	0	0	0	0	0	0
16	Net Profit(+)/Loss(-) for the period(14-15)	168.36	110.11	45.21	278.47	105.30	128.94
17	Paid-up equity share capital-Rs.10/- #	1757.97	1681.47	1681.47	1757.97	1681.47	1681.47
18	Reserves excluding revaluation reserves(as per balance sheet) of previous accounting year to be given in column (5)						1988.37
19	Earning Per Share (EPS) a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.96	0.65	0.27	1.58	0.63	0.77
20	Public shareholding -----Number of shares -----Percentage of Shareholding	7157132 42.56%	7157132 42.56%	7160132 42.58%	7157132 42.56%	7160132 42.58%	7157132 42.56%



21	Promoters and promoter group Shareholding **						
	a) Pledged/Encumbered						
	----Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
	----Percentage of Shares (as a % of the total shareholding of promoter & promoter group)						
	----Percentage of shares (as a% of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-encumbered						
	----Number of Shares	9657552	9657552	9654552	9657552	9654552	9657552
	----Percentage of Shares (as a% of the total shareholding of promoter & promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100%
	----Percentage of shares (as a % of the total share capital of the company)	57.44%	57.44%	57.42%	57.44%	57.42%	57.44%

7,65000 equity shares allotted on preferential basis is yet to be credited in the demat account of the allottees

Notes :-


- 1) The above financial results have been taken on record by the Board of Director's of the Company at its Board meeting held on 14.10.2016
- 2) Company has issued a 20 lacs convertible warrants at a price of Rs.35/- per warrant including premium at a price of Rs.26/- per warrant. Company has call 25% against the same.
- 2) Status of investors complaints (Nos) : Opening Balance as on 01.07.16 - Nil ; Received during the quarter - 8 ; Disposed off during the quarter - 8 ; Closing Balance as on 30.09.16 - Nil.

Place : Tarapur
 Date : 14th October'2016

By Order of the Board of Directors
 Chetan K. Mehta
 Director

For Aarey Drugs & Pharmaceuticals Ltd

Chetan K. Mehta
 Director



The Board of Directors,

AAREY DRUGS AND PHARMACEUTICALS LIMITED,
E-34, M.I.D.C.,
TARAPUR, BOISAR
THANE-401506

Re: Limited Review of the Financial Result for the quarter ended 30th September 2016.

We have reviewed the accompanying statement of unaudited financial results of **AAREY DRUGS & PHARMACEUTICALS LIMITED** for the Quarter and period ended 30th September 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Director. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Review of Interim Review Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under section 133 of companies Act, 2013, Read with Rule 7 of the companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DMKH & Co.
Chartered Accountants
FRN 116886W

Kankani

CA. Manish Kankani
Partner
M.No. 158020
Place: Mumbai
Date: 14th October, 2016

